Related Experiment Video
Updated: Dec 18, 2025

Longitudinal Follow-Up of Urinary Tract Infections and Their Treatment in Mice using Bioluminescence Imaging
Published on: June 14, 2021
Lascufloxacin hydrochloride to treat bacterial infection
R Thakare1, S Singh1, A Dasgupta1
1Division of Microbiology, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, India.
Abstract:
Lascufloxacin hydrochloride (AM-1977) is a novel 8-methoxy fluoroquinolone antibacterial agent with a unique pharmacophore at the 1st and 7th positions of the quinoline nucleus developed by Kyorin Pharmaceutical Co., Ltd. (Tokyo, Japan). It has been approved by the Japanese Ministry of Health, Labour and Welfare (MHLW) for treatment of respiratory tract and ear, nose and throat infections including community-acquired pneumonia and otorhinolaryngological infections, and shows great promise against fluoroquinolone-resistant strains of major pathogens which infect the respiratory tract. It is suitable for treating infections caused by Staphylococcus, Streptococcus, Pneumococcus, Moraxella (Branhamella) catarrhalis, Klebsiella, Enterobacter, Haemophilus influenzae, Legionella pneumophila, Prevotella and Mycoplasma pneumoniae that are sensitive to this drug.
Related Concept Videos
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
Urinary Tract Infection IV: Nursing Management
Drugs for Treatment of Constipation-Predominant IBS
Urine Studies II: Urine Culture and Sensitivity Test
Acute Pyelonephritis II: Diagnostic Studies and Management
Urinary Tract Infection I: Introduction

